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ABSTRACT 
 
Assuming that there is feedback between an expanding cancer system and its organ-typical 
microenvironment, we argue here that such local tumor growth is initially guided by co-existence 
rather than competition with the surrounding tissue. We then present a novel concept that 
understands cancer dissemination as a biological mechanism to evade the specific carrying 
capacity limit of its host organ. This conceptual framework allows us to relate the tumor 
system’s volumetric growth rate to the host organ’s functionality-conveying composite 
infrastructure, and, intriguingly, already provides useful insights into several clinical findings.    
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ARTICLE 
 
Metastasis is a common complication of many solid cancer types and generally indicates 
advanced stage disease. What, however, varies considerably from patient to patient are for 
instance dynamics and extent of the dissemination. To our knowledge, up until now the process 
of metastasis has been primarily investigated from an experimental tumor biology perspective, 
describing it as an intricately complicated process that involves multiple steps including cell 
detachment, cell-matrix interaction, tissue infiltration and angiogenesis [1–4]. While these works 
undoubtedly led to significant insights over the years, a detailed understanding as to the general 
dynamics driving the onset of metastasis has yet to emerge.  
 
It is generally accepted that tumors crucially depend on extrinsic nutrients provided by the host 
[e.g., 5–7] in conjunction with their auto- and paracrine produced growth factors [8]. Here, we 
therefore argue that, for a tumor, ‘success’, with regards to its overall growth would be ill 
defined as merely gaining a competitive advantage over a rapidly failing host organ. Rather, 
characterizing the underlying relationship as coexisting, evolutionary success should be assessed 
by as to how well this tumor manages its interaction with the host site so that continuous 
malignant growth is ensured within a well nourishing since persevering host organ. Following 
this novel conceptual framework, metastasis should be triggered when the carrying capacity of 
the primary host organ (both in terms of biochemistry and biomechanics) is about to be exceeded. 
While the biological processes involved in cancer expansion may lead to some upward 
adjustment of the carrying capacity, presumably these parenchymal and stromal compensation 
mechanisms are limited, and tumor cells will eventually spread to distant sites. We note that the 
so-called ‘carrying capacity’ of a given environment has been widely studied in the area of 
ecology to estimate human population dynamics [9,10]. Moreover, as a parameter, carrying 
capacity has already been implemented in several mathematical models to study the tumor’s 
adaptive responses [11,12], but the idea in these works was still constrained by the point that the 
growth of tumor cell populations is due to competition for limited resources. 
 
We argue that malignant cancer may not be geared towards conquering the host that it so 
critically depends on but, particularly in its early stages, benefits from maintaining a state of co-
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existence. Since there is no apparent benefit for the hosting organ, this ‘co-existing’ relationship 
is profoundly one-sided and, for the case of malignant tumors, overall finite. Ultimately, the 
increasingly aggressive makeup of the cancerous cells overcomes the limited biomechanical and 
-chemical compensation mechanisms available to the original site, then triggering metastasis as a 
mere ‘escape’ mechanism in a futile effort to avoid the inevitable. That is, while such 
dissemination to secondary sites is, according to this new concept, meant to prolong the overall 
coexistence, the mounting damage that it causes to the patient’s delicate physiology makes the 
disease less controllable and thus usually worsens the overall prognosis [e.g., 13]. We conjecture 
that cancer may in fact not fit the usual characterization of an unregulated lopsided growth 
process where dissemination is primarily means of expansive ‘colonialism’, but behaves as a 
coexisting growth process where invasion and metastasis serve as tools to evade the detrimental 
effects of growing microenvironmental constraints. While all this at first may seem rather odd, 
our concept merely argues for continuous feedback between tumor and microenvironment, and, 
within limits, the possibility of dynamic adaptation on both sides. We note that the experimental 
evidence supporting such feedback is mounting [e.g., for a recent review on melanoma-
microenvironment interaction see 14]. Following our hypothesis, the optimization goal of the 
tumor system is maximizing its spatio-temporal expansion rate1 while maintaining the nourishing 
microenvironmental conditions as much as necessary and as long as possible to ‘selfishly’ 
sustain this maximum growth rate.  
 
Moving this qualitative concept now into a more theoretical framework, the carrying capacity, 
CC, of a given host organ denotes the maximum tumor volume, VTum that can be sustained by that 
tissue’s composite volume infrastructure2, VTis, without causing organ malfunction. To properly 
reflect this function-volume relationship, we start with defining CC as   
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛=
Tis
Tis
C
V
F
C 1           (1) 
 
                                                 
1 Employing proteolysis, invasion, adhesion, angiogenesis and related epi/genetic progression.  
2 Comprising biomechanical and biochemical components. 
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where FTis represents the level of specialization or functionality of a tissue (depending on both 
tissue and the parameter (set) used to reflect its functionality). While VTis and CC are being 
defined in volume units, FTis is defined as a non-dimensional parameter for now. We argue here 
that the extent of functional connectivity if not circuitry in ‘evolved’ and thus highly 
differentiated and specialized tissues ensures that FTis equals and more likely exceeds the value 
of its corresponding unit of tissue volume and thus CC ≤ 1. Now, since, at least during the early 
tumor growth phase, 
 
CTum CV ≤           (2) 
 
it follows conceptually that the critical threshold for VTum to trigger the onset of metastasis 
should be ≤ 1. Eq. (2) indicates that the higher the tissue’s function-volume relationship, i.e. the 
more differentiated the host organ, the smaller its CC and thus the smaller the maximum tumor 
volume that this particular host organ can sustain. We note that on-site tumor dissemination or 
invasion involves proteolysis, i.e., enzymatic degradation of adjacent parenchyma. We 
hypothesize that this disruptive local expansion sufficiently damages the tissue’s infrastructure 
and consequently, impacts and ultimately impairs the organ’s functionality. According to Eq. (1), 
any such reduction in FTis will lead to an increase in primary site CC, much like any increase in 
VTis through, for instance, tumor-induced angiogenesis [15]3. 
 
One may further argue that cancer dissemination towards multiple organ sites i, j … n must be 
guided by the premise of a more permissive CC [Total]. However, following a complex systems 
concept4 multi-organ site physiology should constitute a larger increase in F[Total] than in V[Total] 
and, in its non-diseased state, thus overall yield a reduced CC [Total]. Therefore, in order to 
generate any increase in CC [Total] the process of metastasis would have to cause a marked damage 
to multi-organ functionality early on. This should result in a sizeable selection pressure that fuels 
tumor progression on a systemic level and that expands VTum [Total], worsens the patient’s 
                                                 
3 For the case of angiogenesis, this tumor-organ coexistence can be characterized as ‘commensalisms’, as only one 
side, the tumor, benefits from this form of cooperation. In this context, for a recent article on the application of 
‘game theory’ to cancer growth see [16], and for theoretical modeling approaches see e.g. [17] and [18].   
4 The understanding, that a system’s emergent behavior exceeds the mere sum of its component parts. For more 
information on this topic see e.g. [19] and references therein. 
Deisboeck, T.S. & Wang, Z.: Cancer Dissemination 
 5
prognosis and thus reflects the common clinical scenario. That said, the volumetric growth rate 
should however be a more relevant indicator for the impact the cancer systems has, than a given 
volume alone and so we propose that  
 
t
C
t
V CTum
∆
∆≤∆
∆
         (2.1) 
 
Eq. (2.1) states that gaining modest volume over a much larger timeframe is less likely to 
threaten an organ’s carrying capacity, whereas a rapid change even of a relative small tumor 
volume can quickly approximate a set, limited carrying capacity. However, in reality, CC is not 
static either and thus Eq. (2.1) accounts for dynamic (biomechanical and biochemical) tissue 
compensation mechanisms, that require sufficient time to adjust properly and overall are finite. 
Taken together, we deduce from Eqs. (1) and (2.1) that aggressive tumor growth within a highly 
differentiated organ causes early onset of symptoms. That is, according to Eq. (1) CC should be 
rather low to begin with in most mammalian organs, and thus the cancer growth induced ∆VTis (= 
increase in composite tissue infrastructure volume) and/or ∆FTis (= reduction in functionality) 
has to be substantial to expand CC sufficiently, and do so rather quickly, in an effort to delay 
early onset of metastasis. This, in turn, supports the notion that a tumor progresses locally first, 
prior to any metastasis. At later stages, once dissemination occurs, the now systemic disease 
rapidly becomes even more aggressive, i.e. rendering it ‘de facto’ competitive, for the reasons 
detailed above. Taken together, we argue that it is this limit in carrying capacity, both locally and 
globally, which drives cancer system progression and expansion and that therefore ultimately 
threatens the state of coexistence the tumor so critical depends on. 
 
We note that the left term in Eq. (2.1), i.e. ∆VTum/∆t, is not restricted to a particular tumor growth 
model and can follow e.g. logistic, Gompertz or Universal scaling laws [20,21]. Rewriting Eq. 
(1) as
)(
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where the variables k1(t) = 1/FTis(t) and k2(t) = 1/FTis2(t). As FTis(t) > 0 and VTis(t) >0, k1(t) > 0 
and k2(t) > 0. For simplification, VTis(t) is treated in a generic way, i.e. with a unit volume of 1, 
regardless of its real metric volume. Since we argue that VTis(t) is equal to or smaller than FTis(t), 
it follows that FTis(t)>1. Thus, the relation between k1(t) and k2(t) is k2(t) ≤ k1(t). From this, we 
can deduce that the impact a temporary change in VTis has on increasing CC is greater than or 
equal to that caused by dynamic variations in FTis. Combining Eqs. (2.1) and (3), we deduce that 
a sufficient condition, but not a necessary and sufficient condition, for continued tumor growth is  
 
dt
tdF
tVtk
dt
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tktV
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Tis
Tis
Tum
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Eq. (4) summarizes the dynamic relationships between changes in tumor volume, host tissue 
functionality and its composite infrastructure. Specifically, it states that if the growth rate of the 
tumor is less than or equal to the adjustment rate of CC, the host organ’s environmental setting 
remains permissive for on site cancer growth. Consequently, we hypothesize that once the 
tumor’s growth rate exceeds the compensation mechanisms available to the tissue, more 
metastatic phenotypes will be selected within the heterogeneous tumor cell population.  
 
This new theoretical framework offers an intriguing opportunity to conceptualize several 
scenarios that have significance for the clinical situation.  
 
• For instance, the finding that a tumor-induced increase in the rate of change of VTis has 
likely a more substantial impact on moderating the primary or host organ’s CC than a 
change rate reduction in its tissue’s function can achieve, may suggest that the tumor, as 
an opportunistic system, employs neo-infrastructure building processes (and here most 
notably neo-vascularization) first and more so than to operate with infiltrative tissue 
destruction. This then does seem to support our argument of the tumor system initially 
striving for coexistence rather than competition with its nourishing mircoenvironment. 
We note, however, that in increasing VTis, the process of angiogenesis involves 
endothelial cell migration towards the chemoattractant secreting tumor. The latter should 
impact, possibly damage the native parenchymal infrastructure (in addition to the damage 
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done by the advancing tumor cells); hence, by means of reducing FTis tumor, 
angiogenesis may lead to an even more substantial increase in CC. Following this line of 
thought, we conjecture that, in an effort to achieving local control, targeting tumor 
angiogenesis should be more promising clinically than trying to reduce the activity of the 
tumor’s infiltration-mediating enzymes, i.e. proteases. And indeed, recent clinical studies 
showed no improvement of outcome for glioma patients treated with the 
metalloproteinase-inhibitor marimastat [22] whereas studies with anti-angiogenetic drugs 
already demonstrated significant clinical potential [23,24]. 
 
• Secondly, if indeed a high level of functionality per unit volume of tissue is the result of 
evolutionary differentiation, it is reasonable to argue that with increasing age, the rate of 
decline in a tissue’s highly specialized functionality, FTis, exceeds the decay in its 
composite tissue infrastructure, VTis. According to Eq. (1), the result would be an aging-
related increase in the tissues’ CC. Interestingly this scenario could explain why in the 
elderly population the incidence of cancer increases while concomitantly, the process of 
metastasis appears to be slowed down [25–27]. In turn, in younger age patients the 
tissues’ carrying capacity should be relatively low on average and as such tumor 
dissemination would generally start earlier and move faster. Intriguingly, this argument is 
again already supported by clinical findings for younger breast cancer patients (< age 35 
years of age) where aggressive histopathological features, including the number of 
metastatic lymph nodes, relate to significantly higher probability of relapse and thus an 
overall lower 5-year survival [28].  
 
• Lastly, following the same line of thought, any surgical debulking with removal of 
tumor-harboring tissue structure may create an even larger functional damage and as such 
yield an increased carrying capacity for the organ residue. This presents the following 
dilemma: while a ‘total’ resection with tumor-free margins in the healthy tissue is 
common goal in clinics [e.g., 29], following our conjecture, therapeutic intervention 
geared towards aggressively reducing tumor burden can paradoxically render the 
remaining, damaged ‘soil’ [30] more permissive for any tumor cells left behind and thus 
may facilitate recurrence. 
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Admittedly, advancing this theoretical framework into a clinically useful, quantitative method 
seems to pose several formidable challenges at first, such as assessing ‘structure-function’ 
relationships per organ and per patient. However, on a second thought, a multitude of 
quantitative tests is already used in clinical practice including e.g. creatinine clearance tests to 
assess kidney function, lung spirometry tests and enzymatic tests to quantify liver function and 
one can extrapolate, that continuous improvements of available in vivo imaging modalities [31] 
will allow assessing ever smaller structural entities.   
 
We conclude that if our hypothesis holds true, one may have to accept yet arguably should also 
be able to readily exploit that in clinics success in battling advanced-stage disease means 
managing co-existence with the tumor system more so than detect, target and eradicate each and 
every cancer cell in the patient’s body. This innovative therapeutic approach would focus on 
patient-specific assessment and monitoring of the diseased tissues’ dynamically changing 
carrying capacity in an effort to clinically manage its change rate and thus attempt controlling 
tumor expansion. Given the significant impact this would have on oncology-related health care, 
experimental in vitro and in silico studies are warranted and necessary as a first step to test this 
intriguing theoretical framework thoroughly.    
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